(Q39528185)

English

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

scientific article published on 8 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

5

object named as

Naomi Kiyota

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Yu Kataoka

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Toru Mukohara

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hideo Tomioka

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yohei Funakoshi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yutaka Fujiwara

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Masakazu Yashiro

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kosei Hirakawa

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Midori Hirai

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hironobu Minami

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

8 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1352-1360

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-011-9699-0

0 references

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Molecular characteristics of eight gastric cancer cell lines established in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Trastuzumab for gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9699-0

21 January 2018

Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene amplification in gastric and esophageal adenocarcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21655918

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9699-0

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39528185&oldid=1836082720"